Get started
Author

Vivian Huang

Observed names: Huang, Vivian Wai-Mei, V Huang, V W Huang, V huang, V. Huang, V. W. Huang, V.W. Huang, Vivian M. Huang, Vivian W Huang, Vivian W. Huang, Vivian Wai-Mei Huang
Observed institutions: Kurume University, Mount Sinai Hospital, Mount Sinai Hospital, University Health Network, Prince Sattam Bin Abdulaziz University, University of Alberta, University of Calgary, University of Toronto, Lunenfeld-Tanenbaum Research Institute, King Fahd Medical City, Bristol-Myers Squibb (United States), Alberta Innovates, Sinai Health System, InDex Pharmaceuticals (Sweden), Janssen Canada (Canada), King Faisal University
ORCID: 0000-0002-4524-9403
Observed ORCID: 0000-0002-4524-9403
OpenAlex ID: A5008925096
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
2015 · Geoffrey C. Nguyen, Cynthia H. Seow, et al. · Gastroenterology · 473
Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort
2017 · C. Ma, R. N. Fedorak, et al. · Alimentary Pharmacology & Therapeutics · 185
PDF
Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohnʼs Disease
2017 · Christopher Ma, Richard N. Fedorak, et al. · Inflammatory Bowel Diseases · 118
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
2024 · David T Rubin, Jessica R Allegretti, et al. · The Lancet · 113
PDF
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study
2021 · William J Sandborn, Brian G Feagan, et al. · Journal of Crohn s and Colitis · 110
PDF
CD71+ Erythroid Suppressor Cells Promote Fetomaternal Tolerance through Arginase-2 and PDL-1
2018 · Cole Delyea, Najmeh Bozorgmehr, et al. · The Journal of Immunology · 92
Systematic review with meta‐analysis: risk of adverse pregnancy‐related outcomes in inflammatory bowel disease
2020 · Parul Tandon, Vivek Govardhanam, et al. · Alimentary Pharmacology & Therapeutics · 89
Anti-TNF Therapy Within 2 Years of Crohnʼs Disease Diagnosis Improves Patient Outcomes
2016 · Christopher Ma, Candace L. Beilman, et al. · Inflammatory Bowel Diseases · 75
Distance management of inflammatory bowel disease: Systematic review and meta-analysis
2014 · Vivian W Huang · World Journal of Gastroenterology · 75
PDF
The Profile of Human Milk Metabolome, Cytokines, and Antibodies in Inflammatory Bowel Diseases Versus Healthy Mothers, and Potential Impact on the Newborn
2018 · Xuanyi Meng, Garett Dunsmore, et al. · Journal of Crohn s and Colitis · 72
Lower Abundance and Impaired Function of CD71+ Erythroid Cells in Inflammatory Bowel Disease Patients During Pregnancy
2018 · Garett Dunsmore, Petya Koleva, et al. · Journal of Crohn s and Colitis · 67
PDF
Does the Level of Reproductive Knowledge Specific to Inflammatory Bowel Disease Predict Childlessness among Women with Inflammatory Bowel Disease?
2015 · Vivian W Huang, Hsiu-Ju Chang, et al. · Canadian Journal of Gastroenterology and Hepatology · 55
PDF
Noninvasive Methods For Assessing Inflammatory Bowel Disease Activity in Pregnancy
2019 · Parul Tandon, Kristel Leung, et al. · Journal of Clinical Gastroenterology · 54
Review article: a decision‐making algorithm for the management of pregnancy in the inflammatory bowel disease patient
2012 · F. M. Habal, V. W. Huang · Alimentary Pharmacology & Therapeutics · 52
PDF
The risk of venous thromboembolism in women with inflammatory bowel disease during pregnancy and the postpartum period
2019 · Yeon Hee Kim, Birgit Pfaller, et al. · Medicine · 51
Modulatory Effects of Pregnancy on Inflammatory Bowel Disease
2019 · Janine van der Giessen, Vivian W. Huang, et al. · Clinical and Translational Gastroenterology · 51
Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease
2014 · C. Ma, V. Huang, et al. · Alimentary Pharmacology & Therapeutics · 51
The Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
2020 · Kristel K Leung, Parul Tandon, et al. · Inflammatory Bowel Diseases · 50
Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study
2014 · Christopher Ma, Vivian Huang, et al. · Journal of Crohn s and Colitis · 50
PDF
Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response
2014 · Christopher Ma, Vivian Huang, et al. · Journal of Clinical Gastroenterology · 48
Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease
2017 · Christopher Ma, Rowan Lumb, et al. · Inflammatory Bowel Diseases · 47
From mother to baby: antenatal exposure to monoclonal antibody biologics
2018 · Anne Pham-Huy, Manish Sadarangani, et al. · Expert Review of Clinical Immunology · 35
Innovative Online Educational Portal Improves Disease-Specific Reproductive Knowledge Among Patients With Inflammatory Bowel Disease
2018 · Kelsey Wierstra, Reed Sutton, et al. · Inflammatory Bowel Diseases · 35
Within-Stool and Within-Day Sample Variability of Fecal Calprotectin in Patients With Inflammatory Bowel Disease
2016 · Lillian Du, Rae Foshaug, et al. · Journal of Clinical Gastroenterology · 34
Patient awareness of extraintestinal manifestations of inflammatory bowel disease
2012 · Vivian Huang, Ravi Mishra, et al. · Journal of Crohn s and Colitis · 34
Works count: 240
Citation count: 2,699
H-index: 28
I10-index: 48
Year
Topic
Type